Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma

Hodi, F. Stephen; Giobbie-Hurder, Anita; Adu-Berchie, Kwasi; Ranasinghe, Srin; Lako, Ana; Severgnini, Mariano; Thrash, Emily M.; Weirather, Jason L.; Baginska, Joanna; Manos, Michael P.; Doherty, Edward J.; Stafford, Alexander; Daley, Heather; Ritz, Jerome; Ott, Patrick A.; Pfaff, Kathleen L.; Rodig, Scott J.; Yoon, Charles H.; Dranoff, Glenn; Mooney, David J.

doi:10.1158/2326-6066.29457229

Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma

journal contribution

posted on 2025-07-02, 07:24 authored by F. Stephen Hodi, Anita Giobbie-Hurder, Kwasi Adu-Berchie, Srin Ranasinghe, Ana Lako, Mariano Severgnini, Emily M. Thrash, Jason L. Weirather, Joanna Baginska, Michael P. Manos, Edward J. Doherty, Alexander Stafford, Heather Daley, Jerome Ritz, Patrick A. Ott, Kathleen L. Pfaff, Scott J. Rodig, Charles H. Yoon, Glenn Dranoff, David J. Mooney

<p>Supplementary Table 1. CyTOF panel profiles innate and adaptive immune populations in PBMCs.</p>

Funding

Pfizer Foundation (The Pfizer Foundation)

Sharon Crowley Martin Memorial Fund for Melanoma Research

Malcolm and Emily MacNaught Fund for Melanoma Research

E. Michael Egan Melanoma Research Fund

History

Related Materials

1.
DOI - Is supplement to First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma

ARTICLE ABSTRACT

The optimal means to prime for effective antitumor immunity in a patient with cancer remain elusive in the current era of checkpoint blockade. Crafting a strategy to amplify the number and function of CD8+ T cells while blocking regulatory cells should increase immunotherapy efficacy. Biomaterial carriers have been demonstrated in preclinical studies to amplify the effects of immunomodulatory agents, synergistically integrate the effects of different agents, and concentrate and manipulate immune cells in vivo. Herein, we report data from a phase I trial in patients with metastatic melanoma who received the cytokine GM-CSF and the innate Toll-like receptor 9 agonist CpG oligonucleotide admixed with autologous tumor lysate onto a microporous poly-lactide-co-glycolide matrix polymer scaffold that achieves precise control over the spatial and temporal release of immunostimulatory agents in vivo. This materials system (WDVAX) served as a physical antigen-presenting structure to which dendritic cells and other immune-stimulating cells are recruited and activated. In this first clinical trial of a macroscale biomaterial–based vaccine, WDVAX treatment was found to be feasible and to induce immune activation in patients with melanoma.